Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck collaboration — AstraZeneca (Lynparza & Koselugo Oncology Alliance) ($M) ($M)
Form 10-Q / 10-K Note 3/4 Collaborative Arrangements
Latest, FY2025
338
Period ended Dec 31, 2025
Change on a year earlier
-10.6%
378 in FY2024
History
8 years
Since FY2017
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Collaboration — AstraZeneca (Lynparza & Koselugo Oncology Alliance) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 338 | -10.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 378 | +21.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 311 | -36.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 492 | +194.6% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 167 | -32.4% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 247 | +66.9% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 148 | – | Form 10-K (filed 2022-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 2,350 | – | Form 10-K (filed 2020-02-26) ↗ |
Breakdown
What makes up collaboration — astrazeneca (lynparza & koselugo oncology alliance) ($m)
- AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Current receivables from partner ($M)451 · FY2025
- AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Noncurrent receivables from partner ($M)125 · FY2025
- AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Current payables / liabilities to partner ($M)6 · FY2025
- AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M)338 · FY2025
- AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Net R&D cost-sharing expense ($M)36 · FY2025
- AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Commercialization / SG&A expense sharing ($M)133 · FY2025
- AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Intangible asset amortization in Cost of Sales ($M)48 · FY2024
Cite this data
StockData. (2026). Merck Collaboration — AstraZeneca (Lynparza & Koselugo Oncology Alliance) ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_astrazeneca
See every metric in the Merck KPI table. Data updated Oct 26, 2026.